Alkeus Pharma Logo 2024.png
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
23. Oktober 2024 09:00 ET | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14. Mai 2024 16:05 ET | Tenaya Therapeutics, Inc.
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
21. November 2023 16:30 ET | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
26. Oktober 2023 08:30 ET | Tenaya Therapeutics, Inc.
PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
09. Oktober 2023 08:30 ET | Tenaya Therapeutics, Inc.
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
05. Oktober 2023 08:30 ET | Tenaya Therapeutics, Inc.
Tenaya Therapeutics announced that the first patient has been dosed with TN-201 gene therapy.
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
02. Oktober 2023 17:30 ET | Tenaya Therapeutics, Inc.
Tenaya announced the publication of preclinical research in the October 3, 2023, issue of the American Heart Association’s journal, Circulation.
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
21. September 2023 16:05 ET | Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
31. August 2023 16:05 ET | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
09. August 2023 16:05 ET | Tenaya Therapeutics, Inc.
Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401...